FIG 2.

Concurrent emergence of epidermal growth factor receptor (EGFR) mutations and MET amplification. (A) Tumor-response map showing increased genomic diversity through anti-EGFR therapy. (B) Decreased plasma copy number of EGFR and emergence of multiple pathogenic EGFR mutations and MET amplification with cetuximab treatment. (C) Acquired mutations in EGFR domains after cetuximab monotherapy. Actionable variants are highlighted in red. Actionable alterations were annotated using Catalogue of Somatic Mutations in Cancer and genomic visualization tools from cBioPortal were used. VAF, variant allelic frequency.